Kombinationsterapi i 1. linjebehandling af metastatisk kolorektalkræft Data fra et multicenter, randomiseret, kontrolleret klinisk fase III- studie (NO16966) understøtter anvendelsen af Xeloda i kombination med oxaliplatin eller i kombination med oxaliplatin og bevacizumab til 1. linjebehandling af metastatisk kolorektalkræft.
16 Combination therapy in first-line treatment of metastatic colorectal cancer Data from a multicentre, randomised, controlled phase III clinical study (NO16966) support the use of Xeloda in combination with oxaliplatin or in combination with oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.